The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2024

Filed:

Jul. 17, 2020
Applicant:

Arvinas Operations, Inc., New Haven, CT (US);

Inventors:

Andrew P. Crew, Guilford, CT (US);

Michael Berlin, Flemington, NJ (US);

Angela M. Cacace, Haddam Neck, CT (US);

Julian T. Chandler, Old Lyme, CT (US);

Assignee:

ARVINAS OPERATIONS, INC., New Haven, CT (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 417/14 (2006.01); A61K 47/54 (2017.01); C07D 401/04 (2006.01); C07D 487/04 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 417/14 (2013.01); A61K 47/54 (2017.08); C07D 401/04 (2013.01); C07D 487/04 (2013.01); A61K 45/06 (2013.01);
Abstract

The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.


Find Patent Forward Citations

Loading…